ArticleJournal of cardiothoracic surgery2025
Long non-coding RNA SNHG16 promotes tumor progression and cisplatin resistance in esophageal squamous cell carcinoma via miR-497-5p/HK2 axis.
Article in Journal of cardiothoracic surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- AL137246.1 inhibits esophageal squamous cell carcinoma cisplatin resistance by suppressing the transcriptional activity of GLI2 on ABCC1.Molecular genetics and genomics : MGG · 2025Article
- Exosomes in early lung cancer diagnostics: the current state of progress made and prospects.Frontiers in cell and developmental biology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEsophageal squamous cell carcinoma (ESCC) is a prevalent gastrointestinal malignancy characterized by a high incidence and mortality rate. ESCC frequently develops drug resistance during chemotherapy, resulting in diminished clinical efficacy. Previous studies have identified SNHG16, a long non-coding RNA, as a crucial oncogene, but its underlying mechanisms in the biological functions and chemoresistance regulation in ESCC remain unclear.
methodsRT-qPCR and western blotting were utilized to detect SNHG16, miR-497-5p, and HK2 expression in DDP-resistant/sensitive ESCC tissues and cells. In vitro functional experiments were performed by transfecting DDP-resistant ESCC cells lines with sh-SNHG16, including CCK8, flow cytometry, EdU assay, and transwell assay. Mechanistically, the mechanistic aspects and target binding relationship were established through the luciferase reporter assay. In vivo xenograft model was established to examine the impact of SNHG16.
resultsSNHG16 was significantly overexpressed in both DDP-resistant ESCC tissues and cells. Functional in vitro studies demonstrated that silencing SNHG16 significantly inhibited the proliferation, migration and invasion of ESCC cells, induced cell apoptosis, and sensitized DDP-resistant cells to DDP. Moreover, SNHG16 exerted malignant biological behavior in ESCC cells and conferred cisplatin resistance by acting as a sponge for miR-497-5p and regulating HK2.
conclusionsOur findings uncovered that SNHG16 promoted ESCC malignant progression and DDP resistance through the miR-497-5p/HK2 axis, laying the groundwork for deciphering the molecular mechanisms underlying chemotherapy resistance in ESCC and developing new treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.